semaglutide mcas targets MASH molecular pathways beyond weight loss FDA Clears Semaglutide For Cardiac

Intensive protocols: Severe injuries might warrant 5mg twice weekly during acute phases, though this significantly increases cost and peptide use

Shaw JE, Botros FT, Malik R, et al

PMID: Summary Keywords GIP/GLP-1 receptor agonist, glucagon-like peptide 1 receptor agonist, glucocorticosteroids, semaglutide, steroid-induced diabetes, steroid-induced hyperglycaemia Citation Jdrasek A, Lisowska K and Czupryniak L (2026) Evaluation of GLP-1 receptor agonist therapy in the management of steroid-induced diabetes: a narrative review

Patients cholesterol, blood sugar, blood pressure and kidney function labs improve remarkably and their arthritis, fatigue, insomnia and acid reflux improve or are gone completely